Swansea University Medical School

The Li Shu Fan Medical Foundation Donates £1 Million to Establish the RCSEd Dr Li Shu Fan International Professorship

Retrieved on: 
Friday, September 8, 2023
Yee, Learning, Royal college, Series, Professor, Swansea University Medical School, 5th Legislative Council of Hong Kong, Legislative council, Research, Medicine, Royal College of Surgeons of Edinburgh, Royal College of Surgeons, Hong Kong Sanatorium & Hospital, Patient, United Kingdom, Knowledge, Hospital, Health, Veterinary medicine, Pharmaceutical industry, Nursing, Medical device

HONG KONG, Sept. 8, 2023 /PRNewswire/ -- The Li Shu Fan Medical Foundation (the Foundation) and the Royal College of Surgeons of Edinburgh (RCSEd) today made an announcement regarding a donation of £1 million (equivalent to approximately HK$10 million) from the Foundation to RCSEd. The donation will be allocated towards the establishment of the RCSEd Dr Li Shu Fan International Professorship (the Professorship), a ground-breaking initiative launched in collaboration with the Royal College of Surgeons of Edinburgh (RCSEd).

Key Points: 
  • The donation will be allocated towards the establishment of the RCSEd Dr Li Shu Fan International Professorship (the Professorship), a ground-breaking initiative launched in collaboration with the Royal College of Surgeons of Edinburgh (RCSEd).
  • Dr Walton LI Wai Tat, Medical Superintendent of Hong Kong Sanatorium & Hospital, CEO of HKSH Medical Group, and Chairman and Board of Governors of The Li Shu Fan Medical Foundation, explained the reasoning behind the launch of the new professorship.
  • The establishment of the RCSEd Dr Li Shu Fan International Professorship is a momentous milestone in our ongoing commitment to fulfilling the vision of advancing medical education and research.
  • This same vision is encapsulated in his decision to establish The Li Shu Fan Medical Foundation in 1963, which is dedicated to promoting medical education, research, and supporting medical charity.

The Li Shu Fan Medical Foundation Donates £1 Million to Establish the RCSEd Dr Li Shu Fan International Professorship

Retrieved on: 
Friday, September 8, 2023
Yee, Learning, Royal college, Series, Professor, Swansea University Medical School, 5th Legislative Council of Hong Kong, Legislative council, Research, Medicine, Royal College of Surgeons of Edinburgh, Royal College of Surgeons, Hong Kong Sanatorium & Hospital, Patient, United Kingdom, Knowledge, Hospital, Health, Veterinary medicine, Pharmaceutical industry, Nursing, Medical device

HONG KONG, Sept. 8, 2023 /PRNewswire/ -- The Li Shu Fan Medical Foundation (the Foundation) and the Royal College of Surgeons of Edinburgh (RCSEd) today made an announcement regarding a donation of £1 million (equivalent to approximately HK$10 million) from the Foundation to RCSEd. The donation will be allocated towards the establishment of the RCSEd Dr Li Shu Fan International Professorship (the Professorship), a ground-breaking initiative launched in collaboration with the Royal College of Surgeons of Edinburgh (RCSEd).

Key Points: 
  • The donation will be allocated towards the establishment of the RCSEd Dr Li Shu Fan International Professorship (the Professorship), a ground-breaking initiative launched in collaboration with the Royal College of Surgeons of Edinburgh (RCSEd).
  • Dr Walton LI Wai Tat, Medical Superintendent of Hong Kong Sanatorium & Hospital, CEO of HKSH Medical Group, and Chairman and Board of Governors of The Li Shu Fan Medical Foundation, explained the reasoning behind the launch of the new professorship.
  • The establishment of the RCSEd Dr Li Shu Fan International Professorship is a momentous milestone in our ongoing commitment to fulfilling the vision of advancing medical education and research.
  • This same vision is encapsulated in his decision to establish The Li Shu Fan Medical Foundation in 1963, which is dedicated to promoting medical education, research, and supporting medical charity.

National Cancer Center Announces Recipients of 2023-24 Research Fellowship Awards

Retrieved on: 
Thursday, June 29, 2023
Research, Philanthropy, Pharmaceutical, Oncology, Hospitals, University, Genetics, Education, Foundation, Clinical Trials, Science, Biotechnology, Health, UPMC Hillman Cancer Center, DNA, Cleveland Clinic, Duke University Hospital, University of Pittsburgh, NCC, Brain, Therapy, Swansea University Medical School, Prostate cancer, Follicular lymphoma, Johns Hopkins School of Medicine, Cancer, Nebraska Medicine, Coronavirus Scientific Advisory Board, Woman, DNA repair, University of Nebraska Medical Center, Breast, University of California, Colon, Harvard Medical School, National Cancer Center, City, Prostate Cancer Foundation, Melanoma, Rockefeller University, Baylor College of Medicine, Diagnosis, New York University Grossman School of Medicine, Tobacco Products Scientific Advisory Committee, Dana–Farber Cancer Institute, Pharmaceutical industry, Interior design, Doctor of Philosophy, New York University

The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.

Key Points: 
  • The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.
  • National Cancer Center is delighted to report that total funding for the 2023-24 year grew by 9.4% to an annual record of $768,000.
  • “For 70 years, National Cancer Center has sought to identify and fund promising projects by the best up-and-coming cancer research fellows,” said Regina English, Executive Director of the National Cancer Center.
  • The NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; the Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which focuses on research showing particular promise for brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics.

Bloom Health Centers expands its top-tier mental healthcare services to Winchester with the opening of its newest location

Retrieved on: 
Monday, June 19, 2023
Insurance, Swansea University Medical School, TMS, West Midlands CARE Team, Quality of life, WINCHESTER, Multimedia, Chief Medical Officer (Australia), Hospital, Patient, Mental, Growth, Esketamine, Mental health, Feinberg School of Medicine, Mid-Atlantic (United States), Psychiatry, Nursing, Bloom

The expansion strategy has included identifying geographic areas with unserved mental health services and finding ways to get those individuals better access to care.

Key Points: 
  • The expansion strategy has included identifying geographic areas with unserved mental health services and finding ways to get those individuals better access to care.
  • I am looking forward to leading our team of mental health experts to support the wellness needs of Winchester and the surrounding communities."
  • With this new space in Winchester and expanded service area, Bloom can reach a larger audience with its personalized mental health care services.
  • To find the Bloom Health Center location nearest to you and request an appointment online, please visit www.bloomhealthcenters.com .

Dr.Evidence® Appoints Ken Kobayashi, MD, FACP to its Medical Strategy Advisory Board

Retrieved on: 
Tuesday, June 6, 2023
Software, Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Science, Health, MSAB, Kobayashi, Drug development, Swansea University Medical School, Chair, MB, FACP, AB, Janssen, Multimedia, Doctor of Philosophy, AstraZeneca, Bachelor of Science, National Cancer Institute, Criticism of the Food and Drug Administration, SCM, Bachelor of Medicine, Bachelor of Surgery, Novartis, Daiichi Sankyo, MPH, Feinberg School of Medicine, BA, Food, Pfizer, Medical device, Pharmaceutical industry, Washington University in St. Louis, MD

Dr.Evidence is pleased to announce the appointment of Ken Kobayashi, MD, FACP to the MSAB.

Key Points: 
  • Dr.Evidence is pleased to announce the appointment of Ken Kobayashi, MD, FACP to the MSAB.
  • He joins Chair, Calum MacRae, MB, ChB, PhD, BSc, and members, Michael Klag, MD, MPH, Frank Rockhold, PhD, ScM, BA, and David Tovey, MD.
  • View the full release here: https://www.businesswire.com/news/home/20230606005160/en/
    Dr.Evidence® Appoints Ken Kobayashi, MD, FACP to its Medical Strategy Advisory Board.
  • Kobayashi received his MD from Northwestern University Medical School, Chicago, IL, and his AB from Washington University, St. Louis, MO.

The American Diabetes Association Announces 2023 Pathway to Stop Diabetes Grant Recipients

Retrieved on: 
Tuesday, January 31, 2023
MD, University of North Carolina at Pembroke, B cell, University, School, Feinberg School of Medicine, Environment, UNC Gillings School of Global Public Health, Obesity, ADA, Health, Pathway, Research, Brain, Diabetes, Chapel Hill, Face, Metabolism, Blood, Swansea University Medical School, Loma Linda University School of Public Health, Department of Nutrition, Division, Doctor of Philosophy, American Diabetes Association, Pharmaceutical industry, Nursing, Medicine, Endocrinology, DRS

ARLINGTON, Va., Jan. 31, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) announced the two winners of the Pathway to Stop Diabetes® (Pathway) grants, a five-year grant to support breakthroughs in translational science, clinical science, technology, care, and potential cures in the field of diabetes.

Key Points: 
  • ARLINGTON, Va., Jan. 31, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) announced the two winners of the Pathway to Stop Diabetes® (Pathway) grants, a five-year grant to support breakthroughs in translational science, clinical science, technology, care, and potential cures in the field of diabetes.
  • The ADA is proud to support these individuals and their potential to change the face of diabetes care since 2014.
  • "Our Pathway to Stop Diabetes grants create an environment of success for awardees and provides them with the autonomy, resources, and guidance needed to pioneer the next historic advancement in diabetes care.
  • To learn about past and current Pathway award recipients, visit Pathway to Stop Diabetes.

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies

Retrieved on: 
Thursday, November 4, 2021
RNA transfection, Autosome, MD, Lipid, Research, Quality of life, Technology, Biotechnology, University, Osteoclast, US, Disease, Bone disease, Pathology, Osteopetrosis, Patient, Bone density, RNA, Exercise, Transfection, Adult, Lists of diseases, Osteoporosis, CLCN7, Degenerative disease, Sirna, University of L'Aquila, IND, Metabolic bone disease, Bone pain, Indiana, Fracture, Silicon, Therapy, Vickers Venture Partners, Doctor of Philosophy, Genetic distance, Swansea University Medical School, Vaccine, Pharmaceutical industry, Medical imaging

GUILDFORD, England, Nov. 4, 2021 /PRNewswire/ -- SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has exercised its option under its collaboration with the University of L'Aquila, Italy. The license enables SiSaf to develop small interfering RNA (siRNA) targeted via its Bio-Courier® next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) to regulate the expression of a mutant gene expressed by osteoclasts and other cell types responsible for causing the therapeutically neglected rare autosomal dominant disorder type 2 Osteopetrosis (ADO2) in adults.

Key Points: 
  • SiSaf and the University of L'Aquila entered into the research collaboration and licensing agreement last year.
  • Autosomal dominant osteopetrosis type 2 (ADO2), also known as marble bone disease or Albers-Schnberg disease, affects one in every 20,000 individuals.
  • It is marked by increased bone density due to a defect in bone resorption by osteoclasts, a type of bone cell that breaks down bone tissue.
  • The group headed by Prof Teti is recognised worldwide for their research on bone physiology and pathology, including osteoporosis, bone oncology and the rare genetic bone disease osteopetrosis.

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies

Retrieved on: 
Thursday, November 4, 2021
RNA transfection, Autosome, MD, Lipid, Research, Quality of life, Technology, Biotechnology, University, Osteoclast, US, Bone disease, Disease, Pathology, Osteopetrosis, Patient, Bone density, RNA, Exercise, Transfection, Adult, Lists of diseases, Osteoporosis, CLCN7, Degenerative disease, Sirna, University of L'Aquila, IND, Metabolic bone disease, Bone pain, Indiana, Fracture, Silicon, Therapy, Vickers Venture Partners, Doctor of Philosophy, Genetic distance, Swansea University Medical School, Pharmaceutical industry, Vaccine, Medical imaging

SiSaf and the University of L'Aquila entered into the research collaboration and licensing agreement last year.

Key Points: 
  • SiSaf and the University of L'Aquila entered into the research collaboration and licensing agreement last year.
  • Autosomal dominant osteopetrosis type 2 (ADO2), also known as marble bone disease or Albers-Schnberg disease, affects one in every 20,000 individuals.
  • It is marked by increased bone density due to a defect in bone resorption by osteoclasts, a type of bone cell that breaks down bone tissue.
  • The group headed by Prof Teti is recognised worldwide for their research on bone physiology and pathology, including osteoporosis, bone oncology and the rare genetic bone disease osteopetrosis.

Dr. Mahmud Kara of KaraMD Honored as "Lifetime Achiever" by Continental Who's Who

Retrieved on: 
Tuesday, October 5, 2021
Continental, University Hospitals Portage Medical Center, Adviser, ESRD, BPS Barbara Wilson Lifetime Achievement Award, Cleveland Clinic, Inflammation, Health, Ravenna, Anti-aging movement, Medical director, Multimedia, Patient, Loving Memory, American Academy, International Baccalaureate, University, Alternative, Internal medicine, Cleveland, YMCA, Founder, Research, Case Western Reserve University School of Medicine, Department, Organization, Medicine, Greater Cleveland, AMA, Education, National Human Genome Research Institute, Swansea University Medical School, Medical device

HUDSON, Ohio, Oct. 5, 2021 /PRNewswire/ --Dr. Mahmud Kara is being recognized by Continental Who's Who as a Lifetime Achiever in acknowledgment of his work at KaraMD.

Key Points: 
  • HUDSON, Ohio, Oct. 5, 2021 /PRNewswire/ --Dr. Mahmud Kara is being recognized by Continental Who's Who as a Lifetime Achiever in acknowledgment of his work at KaraMD.
  • Dr. Kara is the creator of KaraMD, a line of products focused on digestive support, heart health, and reducing inflammation as the gateway to overall health.
  • To start his education, Dr. Kara received an International Baccalaureate from Vienna, Austria, Geneva, and Switzerland in 1984.
  • Dr. Kara previously practiced at Ravenna Primary Care from 2001-2004, and then at Robinson Memorial Hospital from 2004-2005.

Hearing Restoration For The Deaf: Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

Retrieved on: 
Wednesday, September 15, 2021
University, MHH, BCI, University of Minnesota College of Design, SALT, Hearing loss, Technology, CEO, Breast implant, Doctor of Philosophy, Patient, Animal, Clinical trial, NIH, Medical school, ANI, Cochlea, Biomedical engineering, Solution, Skin, Wallace H. Coulter Department of Biomedical Engineering, Engineering, Cis, Biomedicine, Department, Electrode, Brain, Ear, Partnership, CI, Population, Human, Research, College, Swansea University Medical School, Hannover Medical School, College of Sciences and Engineering (University of Tasmania), Medical device, Pharmaceutical industry

The ANI device technology is being developed as part of an NIH-supported effort between the University of Minnesota, Blackrock Neurotech, MED-EL, Hannover Medical School (MHH), Feinstein, and the University of Utah.

Key Points: 
  • The ANI device technology is being developed as part of an NIH-supported effort between the University of Minnesota, Blackrock Neurotech, MED-EL, Hannover Medical School (MHH), Feinstein, and the University of Utah.
  • "Working with the University of Minnesota, we are able to accelerate a groundbreaking process that implants the electrode array directly into the auditory nerve.
  • The latest funding from Blackrock builds upon a $9.7 million five-year grant from NIH awarded to the University of Minnesota in March 2019.
  • Blackrock Neurotech, formerly known as Blackrock Microsystems, is dedicated to the clinical translation of brain-computer interface (BCI) technology.